Vaccibody AS, a clinical-stage Norwegian biotech, has entered an exclusive licensing deal with Genentech to develop and commercialise a DNA vaccine equipped with neoepitopes specific to a patient’s tumour. The vaccine, VB10.NEO, is designed to induce an immune response that is tailored to the tumours. It has already generated data in several cancers in a Phase 1/2a study.
